{"id":"W2612276480","doi":"10.1093/annonc/mdx093.010","title":"LUME-Meso: Randomised phase II/III study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) followed by maintenance N or placebo (P) in chemo-naïve patients with malignant pleural mesothelioma (MPM)","year":2017,"lang":"en","type":"article","venue":"Annals of Oncology","topic":"Occupational and environmental lung diseases","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":false,"ca_institutions":"Boehringer Ingelheim (Canada)","funders":"","keywords":"Medicine; Internal medicine; Hazard ratio; Pemetrexed; Oncology; Platelet-derived growth factor receptor; Progression-free survival; Phases of clinical research; Placebo; Vascular endothelial growth factor; Gastroenterology; Surgery; Clinical trial; Confidence interval; Chemotherapy; Growth factor; Pathology; Receptor; Cisplatin","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001517748,0.001766307,0.003092244,0.0004986987,0.0004906969,0.001313987,0.00136434,0.001365969,0.008179952],"category_scores_gemma":[0.001052952,0.0010181,0.001956204,0.0004407653,0.001653256,0.0014226,0.0006302038,0.004172296,0.001949407],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001163233,"about_ca_system_score_gemma":0.001598201,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.002242034,"about_ca_topic_score_gemma":0.005301181,"domain_scores_codex":[0.9995696,0.0002132518,0.00002189118,0.000080151,0.0000229689,0.00009207946],"domain_scores_gemma":[0.9993173,0.000114246,0.0001008976,0.00006268094,0.00002844818,0.0003764373],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9742091,0.007837692,0.0005332371,0.0003221748,0.0004370561,0.00003263079,0.0000468507,0.0004592847,0.004374748,0.00009523804,0.0008810898,0.01077077],"study_design_scores_gemma":[0.9299381,0.06739844,0.001291055,0.00001425867,0.000227889,0.00002638605,0.00001787315,0.000192665,0.0003023199,0.00007056617,0.0005098967,0.00001055777],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9860196,0.003404496,0.0007368071,0.0009943402,0.0007632564,0.002967841,0.00192887,0.0002140306,0.002970905],"genre_scores_gemma":[0.9806722,0.003288655,0.001558073,0.001372068,0.0005525244,0.003759035,0.002528975,0.00006480257,0.006203851],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.008179952,"threshold_uncertainty_score":0.02736473,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04067277901438484,"score_gpt":0.3659618327502897,"score_spread":0.3252890537359049,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}